Education
About Us
Working with TipRanks
Follow Us
Adam Morgan Insider Profile
11 Followers
Adam Morgan, Director at Heron Therapeutics, holds 8.82M shares in Heron Therapeutics (Ticker: HRTX), holds 0.00 shares in Alimera (Ticker: ALIM). Most recently, Adam Morgan Bought ― shares of Heron Therapeutics on Aug 12, 2025 for an estimated value of $2.65M.
Profitable Transactions
3 out of 3 Profitable Transactions
Average Return
+69.70%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Adam Morgan holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jul 25, 2023 - Jul 25, 2024
Return:+105.20%
The most profitable trade made by Adam Morgan
Adam Morgan's Trading History
Heron Therapeutics
Aug 12, 2025
Director
Informative Buy
2.65M
$11.56M
Alimera
Sep 16, 2024
―
Uninformative Sell
―
$0.00
List of latest transactions for each holding click on a transaction to see Adam Morgan's performance on stock
You May Also Like
Adam Morgan insider profile FAQ
What is the percentage of profitable transactions made by Adam Morgan?
The percentage of profitable transactions made by Adam Morgan is 100%.
What is the average return per transaction made by Adam Morgan?
The average return per transaction made by Adam Morgan is 69.70%.
What stocks does Adam Morgan hold?
Adam Morgan holds: HRTX, ALIM stocks.
What was Adam Morgan’s latest transaction?
Adam Morgan latest transaction was an Informative Buy of $2.65M.
What was Adam Morgan's most profitable transaction?
Adam Morgan’s most profitable transaction was an Informative Buy of HRTX stock on July 25, 2023. The return on the trade was 105.20%.
What is Adam Morgan's role in Heron Therapeutics?
Adam Morgan's role in Heron Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.